Skip to main content

Fiscal Wizard · Single-issue tearsheet

UTHR / Jun 20, 2026 Run #7266

UTHR

United Therapeutics Corporation

United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. It offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Nebulized Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, it is involved in developing RemunityPRO Pump and Ralinepag for the treatment of PAH;and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. Further, it provides preclinical products, including EVLP/CLES, for lung transplant; UKidney, UHeart, UThymoKidney, a development-stage gene-edited porcine kidneys and hearts for xenotransplantation; ULobe, for allogeneic regenerative medicine; ULung, for autologous regenerative medicine; IVIVA Kidney, for autologous regenerative medicine; miroliver, for allogeneic regenerative medicine; and mirokidney, for allogeneic regenerative medicine. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was founded in 1996 and is headquartered in Silver Spring, Maryland.

Composite verdict

A 79.3 / 100
Bullish setup · Reversal 11 drivers · 3 gates blocking
  • Wedge Pattern
  • Pin Bar
  • Chaikin Money Flow
Consider long call target Δ ~0.70 · ~35 DTE Bullish setup, Grade A → ITM call target

Industry rank 2nd of 85 in Drug Manufacturers - Specialty & Generic

rescore-sweep
Technical synthesisRegime: range
Bull 100%Evidence: High · 21 signals0% Bear
Momentum Bullish 65Mean-reversion Bullish 68

No notable composite patterns — the signals don't cluster into a named setup right now.

Where value comes fromMargin of safety -68%
Asset value $167.18Earnings power value $340.93Price $536.59

Priced above its no-growth earnings power value ($340.93/share) — you're paying for growth and franchise expansion, not just current earnings.

Fundamentals Above average

62.7 / 100

Score-bearing fundamentals shown here exclude gate-only risk checks. · 35 metrics shown.

Strongest
Weakest
EBITDA Margin 86
Margin of Safety 0
Return on Assets 83
Inventory Turnover 0
FCF Margin 82
Cash Conversion Cycle 0

Technicals Bullish

95.9 / 100

Bullish setup leads (Wedge Pattern, Pin Bar, Chaikin Money Flow); bears gated by guards. · 43 signals shown.

Strongest
Weakest
Accumulation/Distribution Line 84
Chaikin Money Flow 84
Wedge Pattern 83

Risk Gates

3 blocking 5 caution

3 guards active, 19 signals gated.

ADX Trend Weakness Blocking

Weak trend strength blocks trend-following signals in either direction.

Realized Volatility Regime Blocking

High-vol regime mutes mean-reversion signals; low-vol regime mutes breakout signals.

Regime Filter Blocking

Blocks signals that oppose the long-term moving-average regime.

Cash Ratio Caution

Visual cash-cushion flag — does not mute signals.

Breakdown

Look under the hood

Empty pane

Pick a category, above, to crack it open.

Every chip in either subscore card drills into the metrics or signals that fed it — including the formula, the threshold band, and what the current reading means for UTHR.